Second Sight Medical Products (EYES) Shares Slide -2.18%

Second Sight Medical Products (EYES) has risen sharply, recording gains of 15.76% in the past 4 weeks. However, the stock has corrected -2.18% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 12% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.33% and the 50-Day Moving Average is 4.45%. Second Sight Medical Products, Inc. has dropped 14.59% during the last 3-month period . Year-to-Date the stock performance stands at -31.41%.


Second Sight Medical Products (NASDAQ:EYES): On Fridays trading session , Opening price of the stock was $3.95 with an intraday high of $4.153. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.71. However, the stock managed to close at $4.04, a loss of 1.94% for the day. On the previous day, the stock had closed at $4.12. The total traded volume of the day was 961,168 shares.

Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Companys product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant, a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU), and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada, Turkey, and at one medical center in Saudi Arabia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.